Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Placebo-controlled, Double-blind, 3-period crossover study to evaluate the phamacodynamics of CX-8998 in young healthy male volunteers

Next Previous
Trial Profile

A Randomised, Placebo-controlled, Double-blind, 3-period crossover study to evaluate the phamacodynamics of CX-8998 in young healthy male volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Suvecaltamide (Primary)
  • Indications Epilepsy; Essential tremor; Neuropathic pain
  • Focus Pharmacodynamics; Proof of concept
  • Sponsors Merck & Co

Most Recent Events

  • 09 Oct 2018 Results presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders
  • 10 May 2018 New trial record
  • 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top